{"disease":{"id":"acute-promyelocytic-leukemia","name":"acute promyelocytic leukemia"},"drugs":{"marketed":[{"drug_id":"daunorubicin","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"arsenic-trioxide","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trisenox","generic_name":"ARSENIC TRIOXIDE","company_name":"Cephalon","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"idarubicin-hydrochloride","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"Idarubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA, Topoisomerase II","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":61,"revenue":null,"mechanism":"Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals."},{"drug_id":"daunorubicine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cytarabine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytarabine","generic_name":"Cytarabine","company_name":"Nippon Shinyaku Co., Ltd.","drug_phase":"marketed","molecular_target":"DNA polymerase","drug_class":"Antimetabolite","quality_score":72,"revenue":null,"mechanism":"Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase."},{"drug_id":"6-mercaptopurine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-Mercaptopurine","generic_name":"6-mercaptopurine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"tretinoin","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retin-A","generic_name":"TRETINOIN","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Nuclear receptor ROR-beta","drug_class":"Retinoid [EPC]","quality_score":58,"revenue":null,"mechanism":"Tretinoin works by binding to and activating nuclear receptors, which helps to regulate cell growth and differentiation."},{"drug_id":"trisenox","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Trisenox","company_name":"German AML Cooperative Group","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Thioredoxin reductase 1, cytoplasmic","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"mercaptopurine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Purixan","generic_name":"MERCAPTOPURINE","company_name":"Stason Pharms","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"mercaptopurine","quality_score":62,"revenue":null,"mechanism":"Purixan works by inhibiting the enzyme responsible for producing prostaglandins, which are involved in inflammation and immune response."},{"drug_id":"chembl-chembl1200976","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"DNA, topoisomerase II","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Idarubicin hydrochloride exerts its effects by forming DNA complexes, inhibiting nucleic acid synthesis, blocking topoisomerase II, and generating DNA-damaging free radicals."},{"drug_id":"idarubicin","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Idarubicin works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death."},{"drug_id":"xaluprine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xaluprine","company_name":"Kjeld Schmiegelow","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":12,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01005277","title":"Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03253848","title":"Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":202,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT02339740","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":158,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT01409161","title":"Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":151,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02899169","title":"Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT00866918","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT04687176","title":"Frontline Oral Arsenic Trioxide for APL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06544109","title":"Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients","phase":"PHASE2, PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":98,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04793919","title":"Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":89,"lead_sponsor_name":"Associazione Italiana Ematologia Oncologia Pediatrica","has_results":false},{"nct_id":"NCT02390635","title":"PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":77,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05832320","title":"Optimum Induction Therapy of Low-risk APL","phase":"NA","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT01445080","title":"Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01472107","title":"Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","has_results":false},{"nct_id":"NCT01139970","title":"Veliparib and Temozolomide in Treating Patients With Acute Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03624270","title":"Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT01253070","title":"Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01588015","title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT00852709","title":"Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT01664897","title":"Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07187505","title":"Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Anhui Medical University","has_results":false},{"nct_id":"NCT01254578","title":"Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06882031","title":"Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"SDK Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03989713","title":"Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Prof. Dr. Richard F Schlenk","has_results":false},{"nct_id":"NCT07203885","title":"AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Harvard Medical School (HMS and HSDM)","has_results":false},{"nct_id":"NCT01869803","title":"Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}